查看文章

The use of biologics in patients with psoriasis has been increasing due to their effectiveness. Exacerbation, or reactivation, of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients with psoriasis is a well-known risk when using biologic therapy. There has very been little information available about the risk of HBV or HCV reactivation in relation to secukinumab therapy. To date, there has been one case study reporting a case of psoriasis vulgaris in an HBV carrier being treated with secukinumab. Using retrospective chart review of the Center for Excellence of Psoriasis and Psoriatic Arthritis (CEPPA) patients at Oregon Health & Science University, we identified a few patients with psoriasis who were treated with secukinumab in the setting of HBV and/or HCV infection. Five adults (three men, two women; age 54-64) with plaque-psoriasis (three with concurrent psoriatic arthritis) were identified. One …